[ad_1]
The vaccine candidate Pfizer-BionTech it is 90% effective in protecting against Sars-Cov-2, according to the first Phase 3 data analyzed by an independent committee that met yesterday, according to the Washington Post. The announcement therefore comes after the race for the White House ended with Biden’s victory. In addition, it has already defined the vaccine in question as “excellent news.”
“I would say it is a historic moment – he says Kathrin Jansen, Head of Vaccine Research and Development at Pfizer – Nothing like this has ever happened before. The world has had to face such a terrible situation, the pandemic, and being able in such a short time to do what usually takes many years. But above all, says Jansen in an interview, “to feel that in the intermediate analysis we have reached amore than 90% effectiveIt was almost amazing. “
In the trial involving 44,000 volunteers, there have been 94 cases of Covid-19 so far: around 9 of these cases occurred in people who had received two doses of the vaccine, “a strong sign of effectiveness.” The data has not yet been published.
According to the independent committee, no particular security concerns arose: side effects They are pain at the injection site, fatigue, and fever, which are more common among young people.
Pfizer and the German biotech company intend to submit the emergency authorization request to the FDA, the US pharmaceutical agency, after the third week of November, when they will have the safety data available, after 2 months of monitoring. in half of the trial participants, in addition to data from the production process. The trial will continue until reaching 164 cases of Covid-19, which should happen in a few weeks.
Of course, a widespread distribution will take some time. As anticipated by the Minister of Health Roberto Speranza, will go to the first quarter of 2021.
Meanwhile, however, the effect of the vaccine announcement literally blows up the stock markets, especially the European ones.
In collaboration with Adnkronos
[ad_2]
